MONDAY, DEC. 13, 2010 BIOWORLD® INSIGHT PAGE 19 OF 30
To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
Copyright © 2010 AHC Media LLC. Reproduction is strictly prohibited.
American College of Rheumatology
(The 74th annual meeting was held Nov. 7 - 11 in Atlanta.)
Company
(Country)
Product Description Indication Status (Date)#
Alder Biopharmaceuticals
Inc. and
Bristol-Myers
Squibb Co.
ALD518 Anti-IL6 antibody Rheumatoid
arthritis
Phase IIa data showed it reduced disease
activity, induced remission and
improved quality of life (11/9)
Bristol-Myers
Squibb Co.
Orencia Abatacept Rheumatoid
arthritis
Phase III data showed similar improvements
in RA disease activity with its
monthly intravenous drug and a new
formulation given in weekly subcutaneous
injections, following a single
intravenous loading dose (11/9)
ChemoCentryx Inc. CCX354 Oral, small molecule
designed to target
the chemokine
receptor CCR1
Rheumatoid
arthritis
Phase I data showed an excellent safety
profile and that once-daily doses produced
greater than 90% receptor coverage
on blood leukocytes throughout
the day (11/10)
Horizon Pharma
Inc.
HZT-501 A single-tablet formulation
of ibuprofen
and high-dose
famotidine
Pain A long-term safety study showed it
was comparable to ibuprofen alone
and had a two-fold reduction in the
incidence of dyspepsia (11/10)
Horizon Pharma
Inc.
Lodotra A modified-release
formulation of prednisone
Rheumatoid
arthritis
Pivotal data showed a statistically significant
and clinically relevant higher
respone rate evaluated by ACR response
critera in patients treated with 5 mg of
Lodotra compared to placebo, in addition
to standard RA therapy, after 12
weeks of treatment (11/10)
Pfizer Inc. Tasocitinib Oral JAK inhibitor;
CP-690,550
Rheumatoid
arthritis
Phase III data showed that 59.8% (low
dose) and 65.7% (high dose) of
patients achieved ACR20, compared to
26.7% for control (11/9)
Roche AG
(Switzerland)
Actemra Tocilizumab Rheumatoid
arthritis
Phase III data showed that it helped
patients with systemic juvenile idiopathic
arthritis; 85% on drug and 24%
on placebo achieved a 30% improvement
(11/9)
UCB SA (Belgium)
and Immunomedics
Inc.
Epratuzumab A monoclonal antibody
targeting
CD22
Active systemic
lupus erythematosus
Phase IIb data showed that certain
doses were associated with a meaningful
and statistically significant
reduction in disease activity in adult
patients (11/10)
UCB SA (Belgium) Cimzia Certolizumab pegol Rheumatoid
arthritis
Phase IIIb data showed it met its primary
endpoint with 51 . 1% of patients
achieving ACR20 score vs. 25.9% in the
control group (11/10)
- Forums
- ASX - By Stock
- ra drugs in development stages
MONDAY, DEC. 13, 2010 BIOWORLD® INSIGHT PAGE 19 OF 30To...
Featured News
Add CBZ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online